NCOA6 and gout: In this context, targeting the NLRP3 ATP hydrolysis motifs (Walker A and B) may hold promise in alleviating NCOA6-induced NLRP3 hyperactivation and could be a novel treatment strategy for inflammatory diseases dependent on NLRP3, including gouty arthritis.